A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02524782

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02524782. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MEDI4166 in Subjects with Type 2 Diabetes Mellitus (T2D).

Study identification

NCT ID: NCT02524782
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: MedImmune LLC; Industry
Enrollment: 103 participants

Conditions and interventions

Conditions

Type 2 Diabetes

Interventions

MEDI-4166 Biological
Placebo Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 7, 2015 (Actual)
Primary completion: Apr 14, 2017 (Actual)
Completion: Apr 14, 2017 (Actual)
Last update posted: Mar 13, 2019

2015 – 2017

United States locations

U.S. sites: 11
U.S. states: 7
U.S. cities: 10

Facility	City	State	ZIP	Site status
Research Site	Anniston	Alabama	36207	—
Research Site	Chula Vista	California	91911	—
Research Site	Jacksonville	Florida	32216	—
Research Site	Miami	Florida	33014	—
Research Site	South Miami	Florida	33143	—
Research Site	Durham	North Carolina	27710	—
Research Site	Raleigh	North Carolina	27612	—
Research Site	Cincinnati	Ohio	45227	—
Research Site	Knoxville	Tennessee	37920	—
Research Site	San Antonio	Texas	78209	—
Research Site	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02524782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 13, 2019 · Synced Nov 15, 2026